

2021-03-05

Press release from the extraordinary general meeting of Vicore Pharma Holding AB (publ)

At the extraordinary general meeting (the “EGM”) of Vicore Pharma Holding AB (publ) (the “Company”) held on 5 March 2021, the below resolutions were mainly passed. Due to the extraordinary situation resulting from the COVID-19 pandemic the EGM was carried out through postal voting, without physical presence.

Approval of the board of directors’ resolution to issue shares

The EGM resolved to approve the board of directors’ resolution to issue 11,200,000 shares at a subscription price of SEK 30.00 per share from 9 February 2021. The right to subscribe for the new shares shall, with deviation from the shareholders’ pre-emption rights, be granted Swedish and international institutional investors as well as certain existing shareholders, who have been identified through a so-called private placement procedure. The reasons for the deviation from the shareholders’ pre-emption rights are that the Company shall, in a timely manner, be able to secure the capital need for the Company’s operations, as well as to broaden the ownership structure of the Company with Swedish and international institutional investors.

For further information regarding the approval of the board of directors’ resolution to issue shares, please refer to the Company’s webpage www.vicorepharma.com. Minutes from the EGM will be made available at the same website no later than two weeks after the EGM.

Gothenburg, 5 March 2021

Vicore Pharma Holding AB (publ)

For further information, please contact:

Carl-Johan Dalsgaard, CEO

Phone: +46 70 975 98 63

E-mail: carl-johan.dalsgaard@vicorepharma.com

Hans Jeppsson, CFO

Phone: +46 70 553 14 65

E-mail: hans.jeppsson@vicorepharma.com

The information was submitted for publication through the agency of the contact persons set out above on 5 March 2021 at 11:30 CET.

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has two drug development programs, VP01, VP02 and VP03.

The VP01 project aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis and COVID-19. The VP02 project is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). The VP02 project focuses on the underlying disease and the severe cough associated with IPF. Both projects are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. The VP03 project includes follow-up molecules for C21.



The company's shares (VICO) are listed on Nasdaq Stockholm's main market. For more information, see www.vicorepharma.com.